Company Description

Clarametyx is combating the formidable challenge of chronic respiratory diseases through an innovative technology platform targeting bacterial biofilms. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which completed a positive Phase 2 study in cystic fibrosis patients in early 2026, and plans to pursue additional mid-stage studies in other chronic respiratory diseases including bronchiectasis.